PD1

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Classical Hodgkin's Lymphoma

Conditions

Relapsed/Refractory Classical Hodgkin's Lymphoma

Trial Timeline

Mar 30, 2017 → Nov 30, 2019

NCT ID

NCT03114683

About PD1

PD1 is a phase 2 stage product being developed by Innovent Biologics for Relapsed/Refractory Classical Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03114683. Target conditions include Relapsed/Refractory Classical Hodgkin's Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03114683	Phase 2	Completed	Mar 30, 2017	Nov 30, 2019	Relapsed/Refractory Classical Hodgkin's Lymphoma

Competing Products

20 competing products in Relapsed/Refractory Classical Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
agenT-797	MiNK Therapeutics	Phase 1	25
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Eribulin mesylate	Eisai	Phase 2	52
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41
ISB 1342	Glenmark Pharmaceuticals	Phase 1	33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	77
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	52
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	33
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	33
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	41
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	33
AZD4573	AstraZeneca	Phase 2	52
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	23
Administration of AZD6738	AstraZeneca	Phase 1	33

Other Products from Innovent Biologics

Taxane and Carboplatin + Short-term SintilimabApproved

Teprotumumab N01 + MethylprednisoloneApproved

IBI311Phase 3

Febuxostat + TigulixostatPhase 3

IBI301 plus CHOP + Rituximab plus CHOPPhase 3